Cargando…

Biochemical Characterization of AGMO Variants Implicated in Relapses in Visceral Leishmaniasis

Detalles Bibliográficos
Autores principales:	Watschinger, Katrin, Keller, Markus A, Golderer, Georg, Coassin, Stefan, Zschocke, Johannes, Werner, Ernst R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946819/ https://www.ncbi.nlm.nih.gov/pubmed/29741738 http://dx.doi.org/10.1093/infdis/jiy090

Ejemplares similares

The Emerging Physiological Role of AGMO 10 Years after Its Gene Identification
por: Sailer, Sabrina, et al.
Publicado: (2021)

When the genome bluffs: a tandem duplication event during generation of a novel Agmo knockout mouse model fools routine genotyping
por: Sailer, Sabrina, et al.
Publicado: (2021)

Adaptations of the 3T3-L1 adipocyte lipidome to defective ether lipid catabolism upon Agmo knockdown
por: Sailer, Sabrina, et al.
Publicado: (2022)

AGMO Inhibitor Reduces 3T3-L1 Adipogenesis
por: Fischer, Caroline, et al.
Publicado: (2021)

The TMEM189 gene encodes plasmanylethanolamine desaturase which introduces the characteristic vinyl ether double bond into plasmalogens
por: Werner, Ernst R., et al.
Publicado: (2020)

A novel assay for the introduction of the vinyl ether double bond into plasmalogens using pyrene-labeled substrates
por: Werner, Ernst R., et al.
Publicado: (2018)

Studying fatty aldehyde metabolism in living cells with pyrene-labeled compounds
por: Keller, Markus A., et al.
Publicado: (2012)

Catalytic residues and a predicted structure of tetrahydrobiopterin-dependent alkylglycerol mono-oxygenase
por: Watschinger, Katrin, et al.
Publicado: (2012)

Unequivocal Mapping of Molecular Ether Lipid Species by LC–MS/MS in Plasmalogen-Deficient Mice
por: Koch, Jakob, et al.
Publicado: (2020)

Monitoring of fatty aldehyde dehydrogenase by formation of pyrenedecanoic acid from pyrenedecanal
por: Keller, Markus A., et al.
Publicado: (2010)

Relationship of Serum Antileishmanial Antibody With Development of Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis Relapse
por: Mondal, Dinesh, et al.
Publicado: (2019)

Miltefosine Rescue Treatment for Visceral Leishmaniasis Relapse Patient
por: Bastola, Anup, et al.
Publicado: (2019)

A gatekeeper helix determines the substrate specificity of Sjögren–Larsson Syndrome enzyme fatty aldehyde dehydrogenase
por: Keller, Markus A., et al.
Publicado: (2014)

Essential role of a conserved aspartate for the enzymatic activity of plasmanylethanolamine desaturase
por: Werner, Ernst R., et al.
Publicado: (2022)

Tricky Isomers—The Evolution of Analytical Strategies to Characterize Plasmalogens and Plasmanyl Ether Lipids
por: Koch, Jakob, et al.
Publicado: (2022)

Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh
por: Mondal, Dinesh, et al.
Publicado: (2019)

Molecular structural diversity of mitochondrial cardiolipins
por: Oemer, Gregor, et al.
Publicado: (2018)

Visceral leishmaniasis
por: Sundar, Shyam
Publicado: (2015)

Impaired Endothelial Nitric Oxide Synthase Homodimer Formation Triggers Development of Transplant Vasculopathy - Insights from a Murine Aortic Transplantation Model
por: Oberhuber, Rupert, et al.
Publicado: (2016)

Predictors of Visceral Leishmaniasis Relapse in HIV-Infected Patients: A Systematic Review
por: Cota, Gláucia F., et al.
Publicado: (2011)

VCAM-1 and ICAM-1 Serum Levels as Markers of Relapse in Visceral Leishmaniasis
por: Makis, Alexandros, et al.
Publicado: (2017)

Congenital Visceral Leishmaniasis
por: Boehme, Catharina C., et al.
Publicado: (2006)

Immunity to Visceral Leishmaniasis
por: Ali, Nahid, et al.
Publicado: (2012)

Treatment of Visceral Leishmaniasis
por: Moore, E M, et al.
Publicado: (2010)

Immunobiology of visceral leishmaniasis
por: Kumar, Rajiv, et al.
Publicado: (2012)

Epidemiology of visceral leishmaniasis
por: Ready, Paul D
Publicado: (2014)

Visceral Leishmaniasis Relapse in HIV Patients—A Role for Myeloid-Derived Suppressor Cells?
por: Van den Bergh, Rafael, et al.
Publicado: (2014)

Two cases of relapsed HIV-associated visceral leishmaniasis successfully treated with combination therapy
por: Mastroianni, Antonio, et al.
Publicado: (2018)

Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
por: Hasnain, Md Golam, et al.
Publicado: (2018)

Is splenectomy an option for multiple relapses in a child with visceral leishmaniasis? A case report
por: Campos, Marcos Adriano Garcia, et al.
Publicado: (2021)

Mucosal Relapse of Visceral Leishmaniasis in a Child with SARS-CoV-2 Infection
por: Colomba, Claudia, et al.
Publicado: (2023)

Alkylglycerol Monooxygenase
por: Watschinger, Katrin, et al.
Publicado: (2013)

Orphan enzymes in ether lipid metabolism
por: Watschinger, Katrin, et al.
Publicado: (2013)

Leishmaniasis and the Sandfly
por: Brooks, A. G.
Publicado: (1949)

Regulation of plasmalogen metabolism and traffic in mammals: The fog begins to lift
por: Dorninger, Fabian, et al.
Publicado: (2022)

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
por: Mina, Roberto, et al.
Publicado: (2020)

Atypical Presentation of PKDL due to Leishmania infantum in an HIV-Infected Patient with Relapsing Visceral Leishmaniasis
por: Celesia, Benedetto Maurizio, et al.
Publicado: (2014)

Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis
por: Kip, Anke E., et al.
Publicado: (2018)

Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV
por: Takele, Yegnasew, et al.
Publicado: (2021)

Visceral Leishmaniasis Treatment, Italy
por: Gradoni, Luigi, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_6p86g4nap2s2u1rkroin5bggjk